[go: up one dir, main page]

WO2000015197A1 - Amelioration du traitement de la maladie de parkinson et des troubles lies par de nouvelles formulations d'associations de carbidopa et de levodopa - Google Patents

Amelioration du traitement de la maladie de parkinson et des troubles lies par de nouvelles formulations d'associations de carbidopa et de levodopa Download PDF

Info

Publication number
WO2000015197A1
WO2000015197A1 PCT/US1998/019404 US9819404W WO0015197A1 WO 2000015197 A1 WO2000015197 A1 WO 2000015197A1 US 9819404 W US9819404 W US 9819404W WO 0015197 A1 WO0015197 A1 WO 0015197A1
Authority
WO
WIPO (PCT)
Prior art keywords
levodopa
carbidopa
layer
sustained release
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/019404
Other languages
English (en)
Inventor
Alan A. Rubin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to PCT/US1998/019404 priority Critical patent/WO2000015197A1/fr
Publication of WO2000015197A1 publication Critical patent/WO2000015197A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group

Definitions

  • a bilayer or multilayer tablet consisting of one layer of sustained release carbidopa-levodopa either adjacent to a layer of immediate release carbidopa-levodopa or separated by an additional excipient layer.
  • the ingredients from each layer are blended separately, then compressed to produce a layered tablet using a suitable layered press .
  • Magnesium Stearate 2.0 EXAMPLE 3 An oral dos.age form, such as a capsule or compressed tablet, containing immediate and sustained release carbidopa-levodopa pellets prepared by the following methods :
  • Appropriate amounts of uncoated core pellets containing immediate release carbidopa-levodopa (step 3) and polymer coated pellets containing sustained release carbidopa-levodopa (step 5) are included in an oral dosage form to provide the desired ratio of immediate and sustained release carbidopa-levodopa.

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne un système d'administration de produit antiparkinsonien par voie orale. Ce système associe la carbidopa et la lévodopa et comporte des compartiments à libération prolongée. Ce système présente un avantage clinique significatif par rapport aux préparations de carbidopa et lévodopa actuellement commercialisées.
PCT/US1998/019404 1998-09-14 1998-09-14 Amelioration du traitement de la maladie de parkinson et des troubles lies par de nouvelles formulations d'associations de carbidopa et de levodopa Ceased WO2000015197A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US1998/019404 WO2000015197A1 (fr) 1998-09-14 1998-09-14 Amelioration du traitement de la maladie de parkinson et des troubles lies par de nouvelles formulations d'associations de carbidopa et de levodopa

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/019404 WO2000015197A1 (fr) 1998-09-14 1998-09-14 Amelioration du traitement de la maladie de parkinson et des troubles lies par de nouvelles formulations d'associations de carbidopa et de levodopa

Publications (1)

Publication Number Publication Date
WO2000015197A1 true WO2000015197A1 (fr) 2000-03-23

Family

ID=22267891

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/019404 Ceased WO2000015197A1 (fr) 1998-09-14 1998-09-14 Amelioration du traitement de la maladie de parkinson et des troubles lies par de nouvelles formulations d'associations de carbidopa et de levodopa

Country Status (1)

Country Link
WO (1) WO2000015197A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005528430A (ja) * 2002-05-29 2005-09-22 インパックス ラボラトリーズ、 インコーポレイテッド 組合せ即時放出および制御放出レボドーパ／カルビドーパ剤型
FR2868700A1 (fr) * 2004-04-09 2005-10-14 Michel Coisy Utilisation de la dopamine ou de ses precurseurs biologiques contre l'algoneurodystrphie.
WO2007002516A3 (fr) * 2005-06-23 2007-05-24 Spherics Inc Formes de dosage ameliorees pour le traitement de troubles moteurs
WO2007073702A2 (fr) 2005-12-29 2007-07-05 Osmotica Corp. Comprime a couches multiples a liberation par triple combinaison
WO2008087882A1 (fr) 2007-01-15 2008-07-24 Kissei Pharmaceutical Co., Ltd. Préparation à libération entretenue de lévodopa de type flottant intragastrique
US9089607B2 (en) 2007-12-28 2015-07-28 Impax Laboratories, Inc. Controlled release formulations of levodopa and uses thereof
EP2921170A1 (fr) * 2002-05-29 2015-09-23 Impax Laboratories, Inc. Combinaison à libération immédiate de lévodopa à libération contrôlée/formes posologiques de carbidopa
US9161911B2 (en) 2008-08-15 2015-10-20 Depomed, Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of CNS disorders
US10098845B2 (en) 2013-10-07 2018-10-16 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US12194150B2 (en) 2020-12-22 2025-01-14 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4900755A (en) * 1986-06-16 1990-02-13 Merck & Co. Controlled release combination of carbidopa/levodopa
WO1994006416A1 (fr) * 1992-09-24 1994-03-31 Jagotec Ag Comprime pharmaceutique capable de liberer un ou plusieurs medicaments a differentes vitesses de liberation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4900755A (en) * 1986-06-16 1990-02-13 Merck & Co. Controlled release combination of carbidopa/levodopa
WO1994006416A1 (fr) * 1992-09-24 1994-03-31 Jagotec Ag Comprime pharmaceutique capable de liberer un ou plusieurs medicaments a differentes vitesses de liberation

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2921170A1 (fr) * 2002-05-29 2015-09-23 Impax Laboratories, Inc. Combinaison à libération immédiate de lévodopa à libération contrôlée/formes posologiques de carbidopa
EP1507518A4 (fr) * 2002-05-29 2010-01-13 Impax Laboratories Inc Association de formes posologiques de levodopa/carbidopa a liberation immediate et controlee
JP2005528430A (ja) * 2002-05-29 2005-09-22 インパックス ラボラトリーズ、 インコーポレイテッド 組合せ即時放出および制御放出レボドーパ／カルビドーパ剤型
FR2868700A1 (fr) * 2004-04-09 2005-10-14 Michel Coisy Utilisation de la dopamine ou de ses precurseurs biologiques contre l'algoneurodystrphie.
WO2005102299A1 (fr) * 2004-04-09 2005-11-03 Michel Coisy Utilisation de la dopamine ou de ses precurseurs biologiques contre l’algoneurodystrophie
WO2007002516A3 (fr) * 2005-06-23 2007-05-24 Spherics Inc Formes de dosage ameliorees pour le traitement de troubles moteurs
WO2007073702A2 (fr) 2005-12-29 2007-07-05 Osmotica Corp. Comprime a couches multiples a liberation par triple combinaison
US8685451B2 (en) 2005-12-29 2014-04-01 Osmotica Kereskedelmi és Szolgáltató KFT Triple combination release multi-layered tablet
US9833412B2 (en) 2005-12-29 2017-12-05 Osmotica Kereskedelmi Es Szolgaltato Kft Triple combination release multi-layered tablet
WO2008087882A1 (fr) 2007-01-15 2008-07-24 Kissei Pharmaceutical Co., Ltd. Préparation à libération entretenue de lévodopa de type flottant intragastrique
US9089607B2 (en) 2007-12-28 2015-07-28 Impax Laboratories, Inc. Controlled release formulations of levodopa and uses thereof
US9463246B2 (en) 2007-12-28 2016-10-11 Impax Laboratories, Inc. Controlled release formulations of levodopa and uses thereof
US9533046B2 (en) 2007-12-28 2017-01-03 Impax Laboratories, Inc. Controlled release formulations of levodopa and uses thereof
US9089608B2 (en) 2007-12-28 2015-07-28 Impax Laboratories, Inc. Controlled release formulations of levodopa and uses thereof
US9901640B2 (en) 2007-12-28 2018-02-27 Impax Laboratories, Inc. Controlled release formulations of levodopa and uses thereof
US9161911B2 (en) 2008-08-15 2015-10-20 Depomed, Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of CNS disorders
US9566258B2 (en) 2008-08-15 2017-02-14 Depomed, Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of CNS disorders
US9937142B2 (en) 2008-08-15 2018-04-10 Depomed, Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of CNS disorders
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US12178918B2 (en) 2013-10-07 2024-12-31 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10688058B2 (en) 2013-10-07 2020-06-23 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10973769B2 (en) 2013-10-07 2021-04-13 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10098845B2 (en) 2013-10-07 2018-10-16 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US11357733B2 (en) 2013-10-07 2022-06-14 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US11622941B2 (en) 2013-10-07 2023-04-11 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US11666538B2 (en) 2013-10-07 2023-06-06 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US12403099B2 (en) 2013-10-07 2025-09-02 Impax Laboratories, Llc Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof
US12064521B2 (en) 2013-10-07 2024-08-20 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US12303605B2 (en) 2013-10-07 2025-05-20 Impax Laboratories, Llc Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof
US12128141B1 (en) 2013-10-07 2024-10-29 Impax Laboratories, Llc Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof
US12178919B2 (en) 2013-10-07 2024-12-31 Impax Laboratories, Llc Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof
US10292935B2 (en) 2013-10-07 2019-05-21 Impax Laboratories, Inc. Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US12274793B2 (en) 2013-10-07 2025-04-15 Impax Laboratories, Llc Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof
US12109185B2 (en) 2020-12-22 2024-10-08 Amneal Pharmaceuticals, LLC Levodopa dosing regimen
US12263148B2 (en) 2020-12-22 2025-04-01 Amneal Pharmaceuticals, LLC Levodopa dosing regimen
US12263149B2 (en) 2020-12-22 2025-04-01 Amneal Pharmaceuticals, LLC Levodopa dosing regimen
US12194150B2 (en) 2020-12-22 2025-01-14 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US12295931B2 (en) 2020-12-22 2025-05-13 Amneal Pharmaceuticals, LLC Levodopa dosing regimen
US12303481B2 (en) 2020-12-22 2025-05-20 Amneal Pharmaceuticals, LLC Levodopa dosing regimen
US12201596B2 (en) 2020-12-22 2025-01-21 Amneal Pharmaceuticals, LLC Levodopa dosing regimen
US12303482B1 (en) 2020-12-22 2025-05-20 Amneal Pharmaceuticals, LLC Levodopa dosing regimen
US12370163B2 (en) 2020-12-22 2025-07-29 Amneal Pharmaceuticals, LLC Levodopa dosing regimen
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US12447139B2 (en) 2020-12-22 2025-10-21 Amneal Pharmaceuticals, LLC Levodopa dosing regimen
US12453710B2 (en) 2020-12-22 2025-10-28 Amneal Pharmaceuticals, LLC Levodopa dosing regimen
US12458616B2 (en) 2020-12-22 2025-11-04 Amneal Pharmaceuticals, LLC Levodopa dosing regimen

Similar Documents

Publication Publication Date Title
US6756056B2 (en) Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa
US6558701B2 (en) Multilayer tablet for administering a fixed combination of tramadol and diclofenac
US5679685A (en) Accelerated release composition containing bromocriptine
US7741373B1 (en) Methods of use of fenofibric acid
EP2921170A1 (fr) Combinaison à libération immédiate de lévodopa à libération contrôlée/formes posologiques de carbidopa
KR100479968B1 (ko) 위장 리파아제 억제제의 용도
MX2010009704A (es) Composiciones farmaceuticas de liberacion modifcada que comprenden micofenolato y procesos de estas.
WO2000015197A1 (fr) Amelioration du traitement de la maladie de parkinson et des troubles lies par de nouvelles formulations d'associations de carbidopa et de levodopa
WO2002087547A1 (fr) Procede ameliore pour preparer une association a dose fixe de quatre medicaments antituberculeux
MXPA06004327A (es) Composiciones y forma de dosificacion para el efecto retardado de levodopa.
CN103249415B (zh) 包含盐酸乐卡地平和缬沙坦的复合制剂及其制备方法
WO2009095395A2 (fr) Compositions pharmaceutiques
HK1001822B (en) Medicinal form for oral application for the once-a-day treatment of hypertension by diltiazem hydrochloride
HK1001822A1 (en) Medicinal form for oral application for the once-a-day treatment of hypertension by diltiazem hydrochloride
HK1050138A1 (en) Novel galenical form for oral administration with prolonged release of molsidomine
CN111084777A (zh) 一种吡贝地尔、左旋多巴与苄丝肼复方缓释三层片剂及其制备方法
US20040192706A1 (en) Method and compositions for treating anxiety
AU2269495A (en) Use of isosorbide-5-mononitrate
MXPA97006492A (en) Use of isosorb 5-mononitrate
KR20210133495A (ko) 옥수수불검화 정량 추출물 및 후박 추출물을 유효성분으로 포함하며 iLet(innovative Low excipient tablet) 기술을 이용한 정제사이즈 축소를 통해 복용 편의성이 향상된 치주질환 예방 또는 치료용 약학적 조성물
JP2009256237A (ja) 固形製剤
HK1124531A1 (en) Retard formulation for pralnacasan
HK1124531B (en) Retard formulation for pralnacasan
KR20100102441A (ko) 제어방출형 고혈압 치료제의 조성물 및 그 제조방법
HK1071847B (en) Dosage forms having prolonged active ingredient release

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase